Dr.ย Antoniย Ribas
MD, PhD
Professor of Medicine & Director, Tumor Immunology Program
corporate_fareUCLA Health Jonsson Comprehensive Cancer Center, Los Angeles
Antoni Ribas
MD, PhD
Dr. Antoni Ribas is one of the world's foremost melanoma oncologists and cancer immunotherapy researchers, based at UCLA Health Jonsson Comprehensive Cancer Center in Los Angeles. He serves as Professor of Medicine, Surgery, and Molecular and Medical Pharmacology at UCLA, and as Director of both the Tumor Immunology Program and the Parker Institute for Cancer Immunotherapy Centre at UCLA.
Dr. Ribas completed his MD at the University of Barcelona in 1990 and his PhD from the Autonomous University of Barcelona, followed by fellowship training in haematology/oncology at UCLA. Over more than three decades, he has built a career at the intersection of translational laboratory science and advanced clinical care, with a primary focus on melanoma. His research was central to the clinical development of pembrolizumab and to defining the mechanisms behind response and resistance to PD-1 checkpoint blockade. He has served as President of the American Association for Cancer Research (2020โ2021) and was elected to the National Academy of Medicine in 2020. Google Scholar records more than 200,000 citations for his published work.
CancerFax can coordinate medical-report review and consultation support for international patients seeking an expert melanoma opinion from Dr. Ribas at UCLA.
Why Consider Dr. Antoni Ribas?
Dr. Ribas is internationally recognised for pioneering work in melanoma immunotherapy and checkpoint inhibitor therapy. His career combines elite academic research with active clinical care for patients with advanced and metastatic melanoma.
Areas of Specialisation
Dr. Ribas focuses on advanced melanoma care, cancer immunotherapy, and the biological mechanisms driving immune response and resistance.
His clinical and research programme spans immune checkpoint inhibitors, molecularly targeted therapy for BRAF-mutant melanoma, adoptive T-cell therapy, and translational clinical trials.
Melanoma Immunotherapy
PD-1 blockade, checkpoint inhibitor combinations, and immune resistance research for advanced and metastatic melanoma.
- arrow_rightPembrolizumab and related anti-PD-1 therapies for advanced melanoma
- arrow_rightCombination checkpoint inhibitor strategies
- arrow_rightBiomarker-driven patient selection for immunotherapy
- arrow_rightPrimary resistance mechanisms including JAK1/2 mutations
- arrow_rightAcquired resistance to anti-PD-1 therapy
- arrow_rightTranslational strategies to overcome resistance
BRAF/MEK Targeted Therapy
Molecularly guided treatment for patients with BRAF-mutant melanoma.
- arrow_rightTreatment planning for BRAF V600-mutant melanoma
- arrow_rightCombination BRAF/MEK inhibitor strategies
- arrow_rightManagement of acquired resistance to targeted therapy
Adoptive T-Cell & Gene-Engineered Therapies
Investigational and clinical-trial approaches using engineered immune cells for selected patients.
- arrow_rightAdoptive cell transfer using TCR-engineered T cells
- arrow_rightClinical trial access at UCLA for selected melanoma patients
- arrow_rightTranslational research linking lab science to patient treatment
Procedures Performed
Clinical services and treatment approaches for melanoma and related conditions
Dr. Ribas provides specialist evaluation, treatment planning, and clinical trial access for patients with advanced melanoma through UCLA Health.
Melanoma Systemic Treatment
Medical OncologyComprehensive planning and administration of systemic therapies for advanced and metastatic melanoma.
Molecularly Guided Targeted Therapy
Targeted TherapyBiomarker-driven treatment planning for patients with actionable mutations.
Clinical Trial Access
Complex DiseaseAccess to investigational treatments and adoptive cell therapy trials at UCLA.
Second Opinion & Complex Case Review
Second OpinionExpert review for patients with complex, refractory, or treatment-resistant melanoma.
Research & Publications
Peer-reviewed contributions to melanoma immunotherapy, targeted therapy, and mechanisms of resistance
Dr. Ribas has an extensive publication record spanning melanoma biology, PD-1 checkpoint blockade, BRAF/MEK therapy, adoptive T-cell transfer, and immune resistance. Google Scholar records more than 200,000 citations for his work.
Dr. Ribas's full publication list is available on Google Scholar and PubMed. His research has over 200,000 citations and continues to shape global melanoma treatment guidelines.
Education & Training
Dr. Ribas completed his medical training in Barcelona and undertook advanced oncology fellowship training at UCLA, where he subsequently built his academic and clinical career.
Clinical Experience
Dr. Ribas joined the UCLA faculty in 2001 and has remained at UCLA Health throughout his career, building one of the world's leading melanoma and tumour immunology programmes. He served as President of the American Association for Cancer Research from 2020 to 2021.
Languages & International
Dr. Ribas consults in the following languages.
CancerFax can coordinate professional medical interpreter support for international patients consulting with Dr. Ribas at UCLA.
CancerFax can coordinate professional medical interpreter support for international patients when required.
How CancerFax Helps You Access Dr. Antoni Ribas
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Antoni Ribas's team โ with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history โ prepared as a structured clinical summary for Dr. Antoni Ribas's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Antoni Ribas before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Antoni Ribas's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Antoni Ribas's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Antoni Ribas's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Dr. Antoni Ribas
Dr. Antoni Ribas specialises in melanoma, including advanced melanoma, metastatic melanoma, and BRAF-mutant melanoma. He is internationally recognised for his work in melanoma immunotherapy and cutaneous oncology at UCLA Health Jonsson Comprehensive Cancer Center.
CancerFax can coordinate medical-report review and consultation support for international patients seeking an expert opinion from Dr. Ribas, subject to UCLA hospital availability and case acceptance. Dr. Ribas consults in English, Spanish, and Catalan.
Submit your medical reports through CancerFax. The CancerFax team will review the documents, prepare the case summary, and coordinate the next steps with UCLA or the doctor's office, subject to availability and case suitability.
A second-opinion request can be submitted through CancerFax with the patient's pathology reports, imaging, treatment history, and relevant test results. Dr. Ribas is particularly well suited to second opinions for patients with advanced melanoma, immunotherapy resistance, or BRAF-mutant disease. The consultation format and availability depend on UCLA's processes.
Dr. Ribas played a central role in the clinical development of pembrolizumab (Keytruda) and in defining how PD-1 checkpoint blockade works in melanoma. His research also covers combination checkpoint inhibitor strategies, BRAF/MEK targeted therapy, adoptive T-cell transfer, and mechanisms of resistance to immunotherapy.
Yes. Dr. Ribas is an active clinical and translational researcher. UCLA lists related clinical trials on his provider profile, and his laboratory runs investigational programmes in adoptive T-cell therapy and engineered T-cell receptor lymphocytes. Eligibility for trial participation depends on the individual case and trial status at the time of enquiry.
Connect with Antoni Ribas Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.